Prestige Biologics Achieves Record-High Quarterly Results
Prestige Biologics has surpassed 10 billion won in quarterly sales for the first time.
According to Prestige Biologics on August 19, revenue for the fourth quarter of fiscal year 2026 (April to June 2026) reached 11.47 billion won. This figure is more than five times higher than the previous quarter's sales of 2.27 billion won.
During fiscal year 2026, Prestige Biologics signed a total of six new contract manufacturing (CDMO) agreements with domestic and international clients, amounting to approximately 41.2 billion won. The company has continued to expand its order base, and these new contracts have been sequentially converted into production and sales, positively impacting this quarter’s performance.
Hot Picks Today
"Expensive, Smelly and Scary"... What's Happened to the "Honeymooners' Paradise" Tourists Have Abandoned?
- Women Who Say "A Husband's Annual Salary of 100 Million Won Is a Given"... Matchmaking CEO: "They Talk About It Like It's Nothing"
- "I Want to Eat Like Koreans..." Foreigners Who Once Opened Ramen Packs Now Keep Gochujang in Their Pantries
- Selection Begins for First Public Prosecution Office Chief... Moon Mooil Named Chair of Candidate Recommendation Committee
- "I'll Give You 53.4 Billion Won to Keep Quiet"... Influencer Reveals Secret Deal; Musk Denies It
Jinwoo Kim, CEO of Prestige Biologics, stated, "Despite the sales growth, the increase in losses was primarily due to impairment of inventory assets, convertible bonds (CB), and certain production facilities. The actual impact on cash flow is limited. Surpassing 10 billion won in fourth-quarter sales demonstrates that our ongoing expansion of the order base is now being reflected in our results."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
